METHOD FOR PREVENTION OF PYOINFLAMMATORY COMPLICATIONS FOLLOWING SURGERY IN MAXILLOFACIAL AREA Russian patent published in 2016 - IPC A61B17/03 A61B10/00 A61K31/201 A61K31/545 A61K38/08 A61P31/04 A61P37/02 A61P41/00 A61M5/32 

FIELD: medicine.

SUBSTANCE: invention can be used for prevention of pyoinflammatory complications following surgery in maxillofacial area. For this purpose, prior to the surgery risk factors of pyoinflammatory complications are detected in patient, and prognostic coefficients are evaluated in points. Thus, age over 70 - 2 points, hypotrophy - 5 points, obesity - 5 points, diabetes mellitus - 5 points, drug habit - 5 points, alcohol abuse - 5 points, chronic renal failure - 5 points; chronic liver failure - 5 points, chronic cardiac failure -5 points, cancer - 5 points, other chronic diseases - 3 points, immunosuppressive therapy - 5 points, long-term ingestion of glucocorticosteroids - 5 points, chemotherapy of cancer - 5 points , radiation therapy - 5 points, infected damage in the area of surgical intervention - 5 points, implantation of foreign materials - 5 points, drainage of postoperative wound - 5 points. In the absence of risk factors, the risk of pyoinflammatory complications is evaluated as low. Only antibiotic prophylaxis is carries out. For this purpose, 30 minutes before the beginning of surgery 2.0 g of ceftriaxone is injected intravenously, then in the postoperative period during 5 days 1.0 gram intramuscularly 2 times a day. If total prognostic score is 2-10 points, there in an average risk of pyoinflammatory complications. Note that antibiotic prophylaxis is added with nutritional support. For this purpose the postoperative period involves intake of Nutridrink nutrient mixture as sip feed by 200.0 ml q.i.d. within 3 weeks. If total prognostic score is over 10 points, the risk of pyoinflammatory complications is evaluated as high. In such case antibiotic prophylaxis and nutritional support is added with immune correction. For this purpose Imunofan is additionally injected in dosage of 1.0 ml intramuscularly once a day. First injection of the preparation is carried out 2 hours before the surgery and continue for 10 days after the surgery.

EFFECT: method provides reducing a risk of pyoinflammatory complications by the differentiated determination of indications and scope of arrangements in patients after surgical treatment in maxillofacial area.

1 cl, 3 ex